Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

16.51 USD UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EST, Jan 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Astellas Pharma Inc

Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November
A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November. 
Tags Market News AGEN RHHBY
From Motley Fool
Gene Therapy-Focused Dyno Therapeutics Adds Astellas To List Partner List With $1.6B Pact
Gene therapy startupDyno Therapeutics Inchas partnered with pharmaceutical giants such asNovartis AG(NYSE: NVS) ... 
Tags Briefs Contracts Trading Ideas
From Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
While the resurgence of COVID-19 cases is driving the demand for vaccines, booster shots, and other related solutions, an aging population is expected to be a key growth driver for the pharmaceutical... 
Tags Stocks / Equities Market News Pharma/Biotech
From TalkMarkets
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Japan's Ministry of Health, Labor, and Welfare (MHLW)has approvedAstellas Pharma Inc's(OTC:ALPMF) ... 
Tags Health Care Market News ALPMF
From Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags INZY ITMR MTEM
From Benzinga
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Astellas Pharma Inc(OTC: ALPMF) has seen thefourth death in its experimental gene therapy trialgained through a $3 ... 
Tags gene therapy News ALPMF
From Benzinga
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags PDSB DRMA MRK
From Benzinga
See Why Astellas Stopped Dosing In Neuromuscular Disease Gene Therapy Trial
Astellas Pharma Inc(OTC: ALPMF) hasvoluntarily paused screening and dosingof additional participants in its ASPIRO ... 
Tags FDA General ALM
From Benzinga
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
TheEuropean Commission (EC) has approvedFibroGen Inc(NASDAQ: FGEN) andAstellas Pharma's(OTC: ALPMF) ... 
Tags ALPMF News AZN
From Benzinga
Here's What Recent News From the FDA Means for AstraZeneca
Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost. 
Tags Market News FGEN AZN
From Motley Fool
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags SIBN TLIS NCNA
From Benzinga
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
TheFDA has issued a complete response letterregarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) ... 
Tags AZN News ALPMF
From Benzinga
Why Investors Should Like BioNTech's Latest Deal With Gilead
There are several pluses for BioNTech in the deal. 
Tags PFE Market News GILD
From Motley Fool
The IPO Recap – Party Is Everything But Over
Last week's 19 IPO week had a lot of life sciences and software. This week, US IPO activity continues at a record with 25 scheduled ... 
Tags USCB IPOs ZENV
From Benzinga
Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer
TheFDA granted full approval and a label expansionforSeagen Inc(NASDAQ: SGEN) -Astellas Pharma ... 
Tags Market News Health Care Benzinga
From Benzinga
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
From TalkMarkets
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Adaptimmune Therapeutics plc(NASDAQ:ADAP) hasreported first preclinical datafrom its HiT targeting mesothelin ... 
From Benzinga
Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics
Cytokinetics Inc(NASDAQ:CYTK)revealed in an SEC filingthatAstellas Pharma Inc(OTCMKTS: ALPMY) is ... 
From Benzinga
Astellas Takes $540M Impairment Charge Of $3B Audentes Buy­out On Gene Therapy Trial Hold
In a financial notice posted earlier today,Astellas Pharma Inc(OTCMKTS: ALPMY) said it was taking an impairment loss of ... 
From Benzinga
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
FibroGen Inc(NASDAQ:FGEN) stock plummeted after hours on Tuesday after amurky disclosure for roxadustat, the ... 
From Benzinga
The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
From Benzinga
Aveo Pharma's Stock Trading Higher On Much Awaited FDA Approval For Tivozanib In Relapsed Kidney Cancer
The FDAhas finally approvedAVEO Pharmaceuticals Inc’s(NASDAQ:AVEO) tivozanib for advanced renal cell ... 
From Benzinga
Astellas Pharma's Fezolinetant Topped Placebo For Reducing Severity Of Menopausal Hot Flash In Phase 3 Studies
Astellas Pharma Plc(OTCMKTS: ALPMY) hasreported positive topline resultsfrom two Phase 3 trials, SKYLIGHT 1 and ... 
From Benzinga
Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings
Seagen Inc(NASDAQ:SGEN) and its collaborating partnerAstellas Pharma Inc(OTCMKTS: ALPMF) havesubmitted ... 
From Benzinga
Where Will Pfizer Be in 5 Years?
What's in store for America's biggest pharmaceutical company and its shareholders? 
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.